On July 6, Akeso (09926.HK) rose 3.32% in regular trading, trading at HK$103.7/share, with turnover of HK$229 million.

On the news front, the innovative drug payment reform continues to drive the biotech sector higher. All five of Akeso's self-developed new drugs across all approved indications have been included in the national medical insurance catalog, while its new drug Qiyoukang has completed its first batch of nationwide shipments, expected to accelerate commercial uptake. Additionally, the national medical insurance authority recently announced 557 drugs passing the initial review for medical insurance catalog inclusion and 54 drugs passing the commercial insurance innovative drug catalog review, marking the substantive advancement of the dual-catalog negotiation mechanism alongside new supportive policies including pre-application mechanisms and 8-year price protection.

Within the Biotechnology sector, peers showed broad-based gains: Remegen up 3.59%, Innovent Bio up 2.79%, 3SBio up 2.61%, SKB Bio up 2.2%, and BeiGene up 0.66%, reflecting continued industry beta resonance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)